Oncology · VEGF InhibitorRegulatory Approvalcommercialmid-term

Sandoz submits ANDA for Tivozanib, marking a new generic entry

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Sandoz24 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/17/2026, 6:33:46 PM

Assessment confidence: 58% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of an ANDA for Tivozanib by Sandoz introduces a new generic competitor, which could significantly alter market dynamics and pricing strategies. Portfolio teams must evaluate the potential impact on market share for existing Tivozanib products and adjust strategies accordingly. Regulatory context from FDA (List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic) supports the near-term read. Assessment grounded in 23 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this generic entry on market share and pricing strategies for Tivozanib. The strongest clinical anchor is A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ClinicalTrials.gov), mechanism alignment (io ); sponsor/company relevance (astrazeneca). In Oncology · VEGF Inhibitor, 4 regulatory and 5 competitive items passed relevance filtering for Sandoz.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application. This submission introduces a potential generic competitor to existing Tivozanib products, impacting market dynamics and pricing.

Regulatory Outlook

Regulatory risk is concentrated around List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic (FDA). Regulatory pathway relevance (nda). The FDA's review of the ANDA will determine the timeline for market entry of the generic, which could influence compliance and approval strategies for existing products.

Key Risks

Elevated medium regulatory exposure for Sandoz could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of a generic competitor may lead to price erosion and affect revenue streams for current Tivozanib products, necessitating strategic adjustments to maintain market position.
Upside for Sandoz may improve if An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov) delivers favorable follow-through.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Portfolio teams should assess the impact of this generic entry on market share and pricing strategies for Tivozanib.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any subsequent approvals or market entries by competitors.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Model-Integrated Evidence (MIE) Industry Meeting Pilot Between FDA and Generic Drug Applicants
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Drug Competition Action Plan | Maximizing scientific and regulatory clarity with respect to complex generic drugs
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Single-Dose Generic Treatment for Influenza
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
ClinicalTrials.govhigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (AstraZeneca)
FDA document
View source
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Management of Abdominal Post-surgical Scar With Ozoaqua Versus Standard Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Modified Mini-PCNL Versus Standard PCNL for Complex Kidney Stones
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Grants Priority Review for BEQALZI (Sonrotoclax) NDA220711
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment

Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Sandoz
Tivozanib

Commercial impact

medium

The entry of a generic competitor may lead to price erosion and affect revenue streams for current Tivozanib products, necessitating strategic adjustments to maintain market position.

Regulatory impact

medium

The FDA's review of the ANDA will determine the timeline for market entry of the generic, which could influence compliance and approval strategies for existing products.

What to watch

Monitor the FDA's review timeline and any subsequent approvals or market entries by competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.